Messenger RNA Coronavirus Disease 2019 (COVID-19) Vaccination With BNT162b2 Increased Risk of Bell’s Palsy: A Nested Case-Control and Self-Controlled Case Series Study
Clinical Infectious Diseases · 2023
DOI: 10.1093/cid/ciac460 ↗Kurz gefasst
Fall-Kontroll-Studie in der Zeitschrift Clinical Infectious Diseases, 2023. Verfasst von Eric Yuk Fai Wan und 24 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Ko…. Hauptthemen laut MEDLINE: Bell Palsy, COVID-19, COVID-19 Vaccines, Facial Paralysis. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background
Observable symptoms of Bell’s palsy following vaccinations arouse concern over the safety profiles of novel coronavirus disease 2019 (COVID-19) vaccines. However, there are only inconclusive findings on Bell’s palsy following messenger (mRNA) COVID-19 vaccination. This study aims to update the previous analyses on the risk of Bell’s palsy following mRNA (BNT162b2) COVID-19 vaccination.
Methods
This study included cases aged ≥16 years with a new diagnosis of Bell’s palsy within 28 days after BNT162b2 vaccinations from the population-based electronic health records in Hong Kong. Nested case-control and self-controlled case series (SCCS) analyses were used, where the association between Bell’s palsy and BNT162b2 was evaluated using conditional logistic and Poisson regression, respectively.
Results
Totally 54 individuals were newly diagnosed with Bell’s palsy after BNT162b2 vaccinations. The incidence of Bell’s palsy was 1.58 (95% confidence interval [CI], 1.19–2.07) per 100 000 doses administered. The nested case-control analysis showed significant association between BNT162b2 vaccinations and Bell’s palsy (adjusted odds ratio [aOR], 1.543; 95% CI, 1.123–2.121), with up to 1.112 excess events per 100 000 people who received 2 doses of BNT162b2. An increased risk of Bell’s palsy was observed during the first 14 days after the second dose of BNT162b2 in both nested case-control (aOR, 2.325; 95% CI, 1.414–3.821) and SCCS analysis (adjusted incidence rate ratio, 2.44; 95% CI, 1.32–4.50).
Conclusions
There was an overall increased risk of Bell’s palsy following BNT162b2 vaccination, particularly within the first 14 days after the second dose, but the absolute risk was very low.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, China.
- Department of Family Medicine and Primary Care, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, China.
- Laboratory of Data Discovery for Health, Hong Kong Science and Technology Park, Sha Tin, Hong Kong Special Administrative Region, China.
- School of Nursing, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, Hong Kong, China.
- School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, China.
- Department of Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, China.
ORCID-Profile: Eric Yuk Fai Wan, Ian Chi Kei Wong
Zitieren
APA
Wan, E. Y. F., Chui, C. S. L., Ng, V. W. S., Wang, Y., Yan, V. K. C., Lam, I. C. H., Fan, M., Lai, F. T. T., Chan, E. W. Y., Li, X., Wong, C. K. H., Chung, R. K. C., Cowling, B. J., Fong, W. C., Lau, A. Y. L., Mok, V. C. T., Chan, F. L. F., Lee, C. K., Chan, L. S. T., …, & Wong, I. C. K. (2023). Messenger RNA Coronavirus Disease 2019 (COVID-19) Vaccination With BNT162b2 Increased Risk of Bell’s Palsy: A Nested Case-Control and Self-Controlled Case Series Study. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciac460
Vancouver
Wan EYF, Chui CSL, Ng VWS, Wang Y, Yan VKC, Lam ICH, et al. Messenger RNA Coronavirus Disease 2019 (COVID-19) Vaccination With BNT162b2 Increased Risk of Bell’s Palsy: A Nested Case-Control and Self-Controlled Case Series Study. Clinical Infectious Diseases. 2023. doi:10.1093/cid/ciac460
BibTeX
@article{Wan2023,
author = {Wan, Eric Yuk Fai and Chui, Celine Sze Ling and Ng, Vanessa Wai Sei and Wang, Yuan and Yan, Vincent Ka Chun and Lam, Ivan Chun Hang and Fan, Min and Lai, Francisco Tsz Tsun and Chan, Esther Wai Yin and Li, Xue and Wong, Carlos King Ho and Chung, Raccoon Ka Cheong and Cowling, Benjamin John and Fong, Wing Chi and Lau, Alexander Yuk Lun and Mok, Vincent Chung Tong and Chan, Frank Ling Fung and Lee, Cheuk Kwong and Chan, Lot Sze Tao and Lo, Dawin and Lau, Kui Kai and Hung, Ivan Fan Ngai and Lau, Chak Sing and Leung, Gabriel Matthew and Wong, Ian Chi Kei},
title = {Messenger RNA Coronavirus Disease 2019 (COVID-19) Vaccination With BNT162b2 Increased Risk of Bell’s Palsy: A Nested Case-Control and Self-Controlled Case Series Study},
journal = {Clinical Infectious Diseases},
year = {2023},
doi = {10.1093/cid/ciac460}
}
EUVIMED